Monthly Archives: March 2018

Page 2 of 712345...Last »

Clinical study data in Mallinckrodts H.

We are delighted that Dr. Furie will talk about the first results of our pilot study on the effects of Acthar in patients with this demanding disease at the forthcoming ACR Annual Meeting, said Steven Romano, M.D., Senior Vice President and Chief Scientific Officer of Mallinckrodt. Mallinckrodt is targeted on completing this important clinical study to determine the great things about Acthar for lupus individuals who frequently have exhausted other good therapeutic options for this difficult-to-treat condition. Continue reading

Benefits Aplenty.

Related StoriesViralytics enters into medical trial collaboration contract with MSDStudy shows rare HER2 missense mutations do not spread breasts cancer on their ownFDA grants accelerated approval for Tagrisso to take care of sufferers with advanced NSCLCCEL-SCI’s Phase III clinical trial is an open-label, randomized, multi-center study made to determine if Multikine administered ahead of current standard of treatment in subjects with Advanced Principal Squamous Cell Carcinoma of the Oral Cavity/Soft Palate will result in an increased overall rate of survival versus the subjects treated with standard of care just. CEL-SCI’s 880 patient trial is expected to be the largest clinical study of mind and neck cancers ever carried out. Continue reading

The mobilization involves civil disobedience at insurance provider offices in Chicago.

They shall not really leave until their demands are met, or they are removed by law enforcement. We are in need of Medicare for All, the real public option.?.. Campaign of non-violent civil disobedience to get rid of insurance abuse Citizens and health care providers who are sick and tired of the condition of our health care system can risk arrest at a New York Aetna health insurance workplace on Tuesday morning hours. The mobilization involves civil disobedience at insurance provider offices in Chicago, Los Angeles, throughout October and various other cities. Continue reading

And Uganda to research nodding syndrome.

‘After they have it, they will die with it, and far earlier than they would have otherwise,’ Scott Dowell, director of the CDC’s Division of Global Disease Recognition and Emergency Response , said . This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health News, an editorially independent information service, is a scheduled system of the Kaiser Family Foundation, a nonpartisan health care policy research corporation unaffiliated with Kaiser Permanente.. CDC investigators working to understand nodding syndrome among East African children Nature News examines the task of a CDC team employed in South Sudan, Tanzania, and Uganda to research nodding syndrome, ‘a poorly understood and seemingly developing problem in eastern Africa.’ The condition, which has struck a large number of children between the age range of five and 15 in the region, ‘impairs both physical development and cognitive development’ and is usually marked by head nodding that ‘occurs when abnormal human brain activity causes a brief lapse in neck muscle tone, leading to the relative check out fall forward,’ the news service notes. Continue reading

The most typical drug-related adverse events had been rash and diarrhea.

Will show new stage Ib data at the 2011 American Culture of Clinical Oncology annual conference in Chicago that indicates merging its investigational therapy afatinib with cetuximab at the utmost tested dosage controlled disease in every treated epidermal growth element receptor -mutation positive patients with non-little cell lung malignancy who developed obtained level of resistance to treatment with a reversible EGFR tyrosine kinase inhibitor . Experts noticed a tumor size reduced amount of up to 76 % over cure amount of up to five a few months. Continue reading

Biotica acquires full privileges to rapamycin analogue plan from Pfizer Biotica Technology Ltd.

‘Our compounds are backed by a solid data package produced by Pfizer, and present proof meaningful differentiation in illnesses with significant unmet want,’ commented Dr. Edward Hodgkin, CEO of Biotica. Because the original Study and License Contract in 2006, Pfizer offers explored the potential of the compounds in a number of diseases, and specifically has profiled candidate medications in multiple sclerosis and systemic lupus erythematosus extensively. Biotica intends to keep advancement in these indications. ‘Pfizer enjoyed a effective collaboration with Biotica,’ stated Dr. Mary Collins, Chief Scientific Officer, Immunology and Autoimmunity Research Device, Pfizer. ‘Your choice to return the program to Biotica was produced within Pfizer’s portfolio review procedure. We wish Biotica achievement as it movements its analogue program forwards.’ Having consolidated its leading placement in polyketide engineering after acquisition of IP from Bristol-Myers Squibb in ’09 2009, Biotica is certainly advancing a solid pipeline of built polyketides including its best-in-course anti-viral cyclophilin inhibitors and the rapamycin analogue plan. Continue reading

Page 2 of 712345...Last »